← Leaderboards
Peter F Wright
Vanderbilt University
$12,188,551
Attributed
$12,188,551
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–06$2M$1.5M$1M$500K$0
'05
'06
Funding mix
By agency
NIH$12,188,551 · 7
By mechanism
U01$12,074,176 · 1
N01$113,783 · 1
M01$592 · 5
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Helen Keipp Talbot$7,247,906
- Catherine C McGowan$12,300,530
- Katherine A Poehling$3,966,679
- Barney S Graham$269,836
- Kathryn Margaret Edwards$34,281,287
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationChild (0-11)Attenuated MicroorganismLive VaccineDrug Screening /EvaluationVaccine DevelopmentInfant Human (0-1 Year)Viral VaccinesAntibody FormationClinical Trial Phase ITissue Resource /RegistryAids Education /PreventionAids VaccinesAidsInterleukin 5Cytotoxic T LymphocyteInfluenza VaccinesLeukocyte Activation /TransformationHelper T LymphocyteInterleukin 4Antigen Antibody ReactionClinical Trials
Grant awards (29)
HIV VACCINE CLINICAL TRIALS UNIT$753,641
U01 · FY2006 · AI · contact PI
HIV VACCINE CLINICAL TRIALS UNIT$1,883,671
U01 · FY2005 · AI
HIV VACCINE CLINICAL TRIALS UNIT$1,932,451
U01 · FY2004 · AI
HIV VACCINE CLINICAL TRIALS UNIT$1,876,165
U01 · FY2003 · AI
HIV VACCINE CLINICAL TRIALS UNIT$1,821,839
U01 · FY2002 · AI
LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE$0
M01 · FY2002 · RR
PARAINFLUENZA VIRUS TYPE 3 LIVE ATTENUATED VACCINE$0
M01 · FY2002 · RR
VA CSP #4 3 VARICELLA ZOSTER VACCINE FOR PREVENTION OF HERPES ZOSTER$0
M01 · FY2002 · RR
EVALUATION OF NEW BACTERIAL AND VIRAL CANDIDATE VACCINE$0
M01 · FY2002 · RR
HIV VACCINE CLINICAL TRIALS UNIT$1,774,800
U01 · FY2001 · AI
VA CSP #4 3 VARICELLA ZOSTER VACCINE FOR PREVENTION OF HERPES ZOSTER$0
M01 · FY2001 · RR
VA CSP #4 3 VARICELLA ZOSTER VACCINE FOR PREVENTION OF HERPES ZOSTER$0
M01 · FY2001 · RR
PARAINFLUENZA VIRUS TYPE 3 LIVE ATTENUATED VACCINE$0
M01 · FY2001 · RR
EVALUATION OF NEW BACTERIAL AND VIRAL CANDIDATE VACCINE$0
M01 · FY2001 · RR
EVALUATION OF NEW BACTERIAL AND VIRAL CANDIDATE VACCINE$0
M01 · FY2001 · RR
EVALUATION OF NEW BACTERIAL AND VIRAL CANDIDATE VACCINE$0
M01 · FY2001 · RR
LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE$0
M01 · FY2001 · RR
LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE$0
M01 · FY2001 · RR
LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE$0
M01 · FY2001 · RR
PARAINFLUENZA VIRUS TYPE 3 LIVE ATTENUATED VACCINE$0
M01 · FY2001 · RR
PARAINFLUENZA VIRUS TYPE 3 LIVE ATTENUATED VACCINE$0
M01 · FY2001 · RR
VA CSP #4 3 VARICELLA ZOSTER VACCINE FOR PREVENTION OF HERPES ZOSTER$0
M01 · FY2001 · RR
HIV VACCINE CLINICAL TRIALS UNIT$2,031,609
U01 · FY2000 · AI
AIDS VACCINE EVALUATION UNITS$113,783
N01 · FY2000 · AI
AGRIPPAL S1/MF59, AGRIPPAL S1 AND PLACEBO INTRANASALLY ADMINISTERED TO ADULTS$592
M01 · FY2000 · RR
VA CSP #4 3 VARICELLA ZOSTER VACCINE FOR PREVENTION OF HERPES ZOSTER$0
M01 · FY2000 · RR
PARAINFLUENZA VIRUS TYPE 3 LIVE ATTENUATED VACCINE$0
M01 · FY2000 · RR
LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE$0
M01 · FY2000 · RR
EVALUATION OF NEW BACTERIAL AND VIRAL CANDIDATE VACCINE$0
M01 · FY2000 · RR